Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 9/20 | 1.00 |
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595830 | 0.96 | MARS2 (0.93) | MARS2SUV39H2EGLN2S1PR2 | |
| SCHEMBL20595873 | 0.96 | MARS2 (1.00) | MARS2EGLN2POLBMAPTRAB9A | |
| SCHEMBL30145156 | 0.96 | MARS2 (1.00) | MARS2EGLN2POLBMAPTRAB9A | |
| SCHEMBL20595875 | 0.92 | MARS2 (1.00) | MARS2SUV39H2EGLN2S1PR2POLB | |
| SCHEMBL20595860 | 0.90 | MARS2 (0.84) | MARS2SUV39H2EGLN2S1PR2POLB | |
| SCHEMBL20596011 | 0.89 | MARS2 (0.93) | MARS2SUV39H2EGLN2S1PR2POLB | |
| SCHEMBL20595950 | 0.88 | MARS2 (0.79) | MARS2LMNAHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL20595864 | 0.88 | MARS2 (1.00) | MARS2EGLN2POLBMAPTRAB9A | |
| SCHEMBL20596363 | 0.84 | MARS2 (0.74) | MARS2EGLN2LMNA | |
| SCHEMBL30145085 | 0.84 | MARS2 (0.74) | MARS2EGLN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | claimed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885SUV39H2 1995/4885EGLN2 1042/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885SUV39H2 1739/4885EGLN2 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.